Abstract Hypertrophy of myocytes in the heart ventricles is an important adaptation that in vivo occurs in response to a requirement for increased contractile power. It involves changes at the level of gene transcription, stimulation of the rate of protein synthesis (translation), and increased assembly of myofibrils. There is mounting evidence of the involvement of reversible protein phosphorylation and dephosphorylation in most of these processes. Protein kinase C, mitogen-activated protein kinases, and transcription factors have been implicated in the modulation of the transcriptional changes. Activation of translation may also be mediated through protein phosphorylation/dephosphorylation, although this has not been clearly established in the heart. Here we provide a critical overview of the signalling pathways involved in the hypertrophic response and provide a scheme to account for many of its features. 
Biology of cardiac (ventricular) hypertrophy

Cardiac hypertrophy in vivo
The adult ventricular myocyte is a terminally differentiated cell which withdraws from the cell cycle during the perinatal period. The contribution of myocytes to the clinical syndrome of "cardiac hypertrophy" thus represents a true hypertrophy of these cells (i.e. an increase in the content of cellular components in the absence of cell division). We confine this review to the ventricular myocyte since relatively little is known about atrial myocyte hypertrophy. Global hypertrophy of the left or right ventricles is an important (and frequently life-saving) adaptation occurring in response to a demand for increased cardiac contractile power and pressure-volume work (reviewed in [1] [2] [3] [4] [5] ). Two forms can broadly be distinguished (reviewed in [6] ). In "pressure-overload" (concentric) hypertrophy, which is seen typically in hypertensive states, for example, the ventricular wall is grossly thickened in the absence of chamber enlargement. It is associated with an increase in myocyte cross-sectional area relative to cell length, with parallel deposition of sarcomeres [7] [8] [9] . In "volume-overload" (eccentric) hypertrophy, which is seen typically in valvular incompetence or other situations where cardiac output is increased at normotensive pressures, chamber volume and radius are enlarged, with a thickening of the ventricular wall in proportion to the chamber radius. This form is associated with an increase in myocyte length relative to cross-sectional area, with deposition of sarcomeres in series [10] . Localized ventricular hypertrophy may follow the loss of myocytes associated with myocardial infarction (ventricular "remodelling") or may be observed in certain inherited diseases (e.g. hypertrophic cardiomyopathy). The hypertrophic cardiomyopathies characterized thus far are associated mainly with mutations in myofibrillar proteins. In its early phase, hypertrophy allows the heart to maintain or increase its cardiac output (the "compensated" state). However, in the longer term, ejection fraction may decrease and heart failure, with its associated morbidity and mortality, may ensue (the "decompensated" state). The determinants of progression from hypertrophy to failure are not understood, but some biochemical explanations are beginning to emerge [11] .
Biochemical and morphological characteristics of hypertrophy
How should hypertrophy of the ventricular myocyte be defined? In addition to increased cell volume and profile (i.e. increased apparent cell area on microscopic examination, to which cell "spreading" could admittedly contribute), accumulation of total protein, and increased myofibrillar assembly, there are changes in the patterns of protein and gene expression that distinguish hypertrophic growth from normal maturational growth both in vivo and in cultured ventricular myocytes (reviewed in [1] ). Some of these changes are also seen in ventricular remodelling [12] and following the development of heart failure [13] . However, there are also examples in the literature of dissociation of the transcriptional changes from the hypertrophic response (see e.g. [14] ). On exposure of myocytes to hypertrophic stimulation, immediate early genes encoding transcription factors (c-jun, c-fos, Egr-1) are rapidly and transiently expressed, but there is concern that this response is relatively unspecific. One longer term feature of hypertrophy involves the recapitulation of a "foetal" programme of gene expression with re-expression of atrial natriuretic factor (ANF) in the ventricular myocyte. This is common to both pressure-and volume-overload hypertrophy [15] . Other characteristics of the "foetal" programme appear to be more specific for pressure-overload hypertrophy, and include up-regulation of skeletal muscle α-actin and β-myosin heavy-chain expression [15] . Constitutively expressed contractile protein genes (cardiac muscle α-actin, ventricular myosin light-chain-2) are also up-regulated in the longer term, and this is presumably common to both pressure-and volume-overload hypertrophy. In contrast, expression of sarcoplasmic (endoplasmic) reticulum Ca 2+ -ATPase 2a is decreased in pressure-overload hypertrophy ( [15] and reviewed in [16] ). These changes in gene expression are useful experimental indices of hypertrophy, with re-expression of the ANF gene being probably the most popular. The ANF-related peptide, B-type (or brain) natriuretic peptide, is expressed throughout hypertrophy [17] , and measurement of its plasma levels may be useful in the diagnosis of cardiac hypertrophy and failure in man [18] . Gene expression is regulated partly by untranscribed sequences in the promoter regions lying 5' to the transcriptional start site. Thus, the 638-bp 5' regulatory sequence of the ANF gene is sufficient to confer inducibility by hypertrophic agonists in cultured ventricular myocytes [19, 20] . The specific sequences involved in the regulation of the expression of the ANF gene and other genes associated with hypertrophy are currently under investigation in many laboratories (see, e.g. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] ).
In addition to transcriptional regulation, control must also exerted at the level of protein accumulation because stimulation of both processes is necessary for the expression of the hypertrophic phenotype. Thus, in addition to causing changes in gene expression, hypertrophic stimuli increase the overall rate of protein synthesis translation (reviewed in [33, 34] ). Indeed, some investigators simply equate stimulation of protein synthesis to hypertrophy (mistakenly in our view), but equally the importance of translation in myocyte hypertrophy is often ignored. There may be other levels of control that still need to be investigated fully, including control of nuclear export of mRNA species, mRNA stability and degradation (see e.g. [35] ), and protein degradation.
In vivo, one hypothesis relating to the origins of myocyte hypertrophy is that a variety of factors (vasoactive peptides, peptide growth factors, neurotransmitters, etc.; see Table 1 ) are released locally and some of these increase contractile power. These extracellular factors act at their transmembrane receptors to trigger a series of intrac-ellular signalling events which, in addition to being inotropic, ultimately promote hypertrophy. A number of protein kinases are involved which may regulate both transcription and translation. Phosphorylation of nuclear trans-acting transcription factors [which bind to specific cis-acting regulatory (untranscribed) elements in the promoter regions of genes] modulates gene transcription. Similarly, the phosphorylation of protein factors involved in translation modulates their ability to activate this process.
Experimental systems
Extensive use has been made of neonatal rat ventricular myocytes in primary culture, originally described by Simpson in the early 1980s [36, 37] . These cells can be maintained in culture for 2-5 days (i.e. long enough to detect changes in morphology and gene expression) without the loss of the phenotype. On exposure to hypertrophic stimuli, the myocytes simulate the hypertrophic response in the adult animal in vivo with reasonable accuracy. However, the situation in vitro probably differs from that in vivo because, almost invariably, a hyperphysiological concentration of a single agonist is used, and this is sufficient to produce a full hypertrophic response. In vivo, a number of agonists present at subsaturating concentrations may interact to produce the response.
Perfused adult rodent hearts and isolated cardiac myocytes have also been used extensively for acute investigations of protein turnover and intracellular signalling, but these preparations are not viable for sufficient periods to allow changes in amounts or species of protein to be investigated. There are numerous in vivo models of hypertrophy (e.g. pressure-overload hypertrophy induced by aortic constriction), but experimental conditions are difficult to control. A more fruitful in vivo approach lies in the use of transgenic mice [38] [39] [40] with conditionally expressing transgenics likely to be most useful in the future [41] . In combination with a surgical procedure such as aortic constriction, transgenic mouse models represent a powerful approach for the study of hypertrophy in vivo [42, 43] .
Hypertrophic stimuli
We consider an agonist to be hypertrophic only if it (a) increases myocyte size and myofibrillar assembly, and (b) induces a hypertrophic pattern of gene expression. Agonists that only increase protein synthesis (e.g. insulin [33]) are not discussed. To seek to identify a single agonist responsible for all aspects of myocyte hypertrophy in vivo is probably a mistake. The likelihood is that many agonists present at subsaturating concentrations act at different stages in the development of this complex adaptation. Endothelin-1 (ET-1) and α 1 -adrenergic agonists are amongst the prime hypertrophic agents so far identified (reviewed in [44] [45] [46] [47] ). Angiotensin II (ANG II) is a candidate, but whether it is directly hypertrophic is controversial (see e.g. [48, 49] ; for a review see [50] ). Its hypertrophic action may depend on its ability to stimulate the release of paracrine factors [51, 52] . Furthermore, hearts of ANG II receptor type 1a "knockout" mice still hypertrophy in response to pressure overload in vivo [53, 54] , a state that is known to activate the renin-angiotensin system (reviewed in [55] ). However, in this model, participation of the type 1b ANG II receptor cannot be excluded. Mice over-expressing the ANG II receptor type 1a are not very informative because cardiac morphology and excitation-contraction coupling is distinctly abnormal, and the mice die shortly after birth [56] . ET-1 and α 1 -adrenergic agonists (and ANG II) act through G protein coupled receptors (GPCRs) in the heart, particularly those of the G q /G 11 subfamily (reviewed in [46, [57] [58] [59] ). ET-1 and α 1 -adrenergic agonists may also act at G i /G o GPCRs (reviewed in [46, 57, 58]), as shown by sensitivity to pertussis toxin (PTX).
Other hypertrophic agonists include peptide growth factors which signal through receptor protein tyrosine kinases (RTPKs; e.g. fibroblast growth factors [60, 61] and insulin-like growth factor-1 (IGF1) [62] [63] [64] ). The newly identified hypertrophic agonist cardiotrophin-1 (CT-1) appears to utilize signalling pathways unrelated to G q /G 11 protein coupled receptors, or receptor protein tyrosine kinase (RPTKs). It was first isolated from medium conditioned by mouse embryoid bodies and has subsequently been cloned [49] . CT-1 is a cytokine with homology to leukaemia inhibitory factor and interleukin 6, and acts through the gp130-linked subgroup of cytokine receptors. One interesting aspect of CT-1 is that in cultured ventricular myocytes it induces patterns of gene expression and morphological changes that are more akin to those seen in "volume-overload" hypertrophy in vivo [65] . This contrasts with α 1 -adrenergic agonists and ET-1 which induce a "pressure-overload" type of hypertrophy in this model system. This is the first indication of a biochemical cause for the morphological differences between the two principal patterns of hypertrophy observed in vivo. A number of interventions that are poorly defined biochemically also induce the hypertrophic phenotype. These include mechanical deformation by stretch [66-69] (reviewed in [3, 70, 71] ), hypoxia [72] , and cell-cell contact [73] . Stretch-induced hypertrophy does not seem to be mediated by the opening of sarcolemmal "stretch-activated" ion channels [74] . The hypertrophic action of some these stimuli may be mediated by the release of autocrine/paracrine factors such as ET-1 [72, 75] 
G protein coupled receptors: coupling of ligand binding to hydrolysis of membrane phospholipids
Binding of agonists such as ET-1 to heptahelical transmembrane G q /G 11 protein coupled receptors causes the associated trimeric G q /G 11 proteins (α.GDP.βγ) to dissociate into α q /α 11 subunits and βγ dimers, with exchange of GTP for GDP on the α-subunits (reviewed in [93, 94] Transfection experiments have directly implicated α q in the hypertrophic response since expression of constitutively activated α q in ventricular myocytes stimulates PtdIns (4,5)P 2 hydrolysis and expression of ANF [102] . Furthermore, the stimulation of ANF expression by phenylephrine (PE) is attenuated by microinjection of neutralizing antibodies against α q [102] . However, at least one study has suggested that G i /G o is also involved in hypertrophy [103] . Extending the findings on α q to the in vivo situation, transgenic mice expressing either a constitutively activated (G q -coupled) α 1B -adrenoceptor [104] or overexpressing the wild-type α q protein [105] develop hypertrophy. The overexpression of α q modifies the response to pressure overload [11] . Whereas wild-type mice exhibit a compensated concentric hypertrophy, the transgenic mice decompensate and exhibit an eccentric hypertrophy with decreased ejection fraction and heart failure [11] . Expression of the C-terminal domain of α q that interacts with the intracellular domains of G q /G 11 GPCRs and inhibits signalling also attenuates cardiac hypertrophy following aortic constriction [106] . However, it does not affect normal maturational growth [106] . Although these findings [106] do not identify the agonist(s) responsible for this form of pressure-overload hypertrophy, they further implicate G q /G 11 protein coupled receptors in the hypertrophic response.
There are alternative pathways of DG production apart from PLCβ-mediated hydrolysis of PtdIns (4,5)P 2 in myocytes. DG may be formed from another membrane phospholipid, phosphatidylcholine, which is first hydrolyzed by phospholipase D (PLD) to phosphatidate (reviewed in [107, 108] ). Phosphatidate is subsequently converted to DG and P i by a phosphatidate phosphohydrolase. PLD is activated in ventricular myocytes by agonists such as phorbol esters (activators of PKC; see below) and ET-1 [109, 110] . The activation of PLD by ET-1 is dependent on PKC, but the mechanism through which PKC activates PLD is obscure (reviewed in [108] ). The activation of PLD may allow a sustained rise in DG concentrations to maintain the activation of DG-regulated PKCs, but this has not been clearly established. A third enzyme that produces DG is PLCγ, which hydrolyzes PtdIns (4,5)P 2 . Activation of PLCγ is frequently associated with activation of RPTKs. Little is known about PLCγ in the ventricular myocyte, other than that it can be activated by purinergic receptors and may represent a major pathway for PtdIns (4,5)P 2 hydrolysis [111] . In the heart there may be subtle variations in the details of these general pathways of DG production. Thus the rapid release of InsP 2 rather than InsP 3 in atria exposed to norepinephrine has been taken as evidence that PtdIns (4)P rather than PtdIns (4,5)P 2 is a significant source of DG [112] . This pathway would allow formation of DG in the absence of formation of InsP 3 .
Regulation of protein kinase C and its involvement in hypertrophy DG is the physiological activator of two of the three PKC subfamilies (reviewed in [98, 113] ). The PKC family of phospholipid-(phosphatidylserine-) dependent Ser/Thr protein kinases consists of at least 11 isoforms (see Table  2 ). Whether the individual isoforms possess specific cellular roles, or whether there is gross redundancy is unclear. Three subfamilies have been identified on the basis of their domain structure which dictates their requirements for Ca 2+ and DG (see Table 2 ). The "classical" or "conventional" PKCs (cPKCs) require both Ca 2+ and DG for activation. The "novel" PKCs (nPKCs) are Ca 2+ independent but require DG for activation. Because DG is a hydrophobic molecule, it is retained in the membrane following its formation. Activation of cPKCs and nPKCs by the binding of DG is thus associated with their translocation from the soluble fraction of the cell to the membrane fraction ( Fig.  1) . This allows the activation of individual isoforms to be assessed by cell fractionation and immunoblotting with isoform-specific antibodies. Activation of the "atypical" PKCs (aPKCs) is independent of both Ca 2+ and DG, and their physiological activators have not been identified unambiguously. Another PKC homologue, PKD/PKCµ, has not yet been fully characterized or allocated to a single PKC subfamily (see [114, 115] for most recent details) but may be more closely related to the Ca 2+ /calmodulin kinase II family than to the PKCs. Phorbol esters such as phorbol 12-myristate 13-acetate (PMA) which, unlike DG, are not rapidly metabolized, substitute for DG and acutely produce a powerful and sustained activation of cPKCs/ nPKCs. PKCµ/PKD is also activated by PMA, but this is thought to be dependent on activation of cPKCs/nPKCs. Chronic activation of the cPKCs/nPKCs with phorbol esters leads to their downregulation presumably because of an increased susceptibility of the activated forms to proteolysis. Acute and chronic treatments with phorbol esters have been used to implicate cPKCs/nPKCs in biological responses, the former stimulating cPKC/nPKC-dependent pathways and the latter inhibiting agonist-stimulated cPKC/nPKC-dependent responses.
As with all tissues, the rat heart expresses a variety of PKC protein isoforms (see Table 2 PKCs are strongly implicated in the hypertrophic response, with phorbol esters mimicking the hypertrophic actions of ET-1 and PE [125, 126] . However, no one particular isoform has been implicated since transfection of a variety of constitutively activated PKC isoforms into ventricular myocytes [127] [128] [129] or cardiospecific overexpression of wild-type cPKCβ I in transgenic mice [130] induces the expression of a hypertrophic gene programme. These transgenic mice display many of the gross anatomical and contractile features of the hypertrophied heart, which can be reversed by the cPKCβ-selective inhibitor LY333531 [130] .
The mitogen-activated protein kinase cascades
General aspects
The mitogen-activated protein kinase (MAPK) superfamily of protein Ser/Thr kinases is a widely distributed group of enzymes that has been highly conserved through evolution. There are at least three subfamilies of the MAPKs: the extracellularly responsive kinases (ERKs), the c-Jun N-terminal kinases (JNKs) which are also known as the stress-activated protein kinases (SAPKs), and the p38-MAPKs (reviewed in [131] [132] [133] [134] [135] ). Some of their properties are shown in Table 3 . The ERKs appear to be involved predominantly in anabolic processes (cell growth, division and differentiation) whereas the SAPKs/JNKs and the p38-MAPKs are involved in cellular responses to pathological stresses and cytotoxic agents. Whether the SAPKs/JNKs and p38-MAPKs promote survival or are involved in cell necrosis/apoptosis remains to be definitively established (reviewed in [132] ), although a recent report has suggested that one isoform of p38-MAPK (the α-isoform) is pro-apoptotic in ventricular myocytes [136] . All MAPKs are proline-directed protein kinases and preferentially phosphorylate Ser/Thr residues within a ProXaa-(Ser/Thr)-Pro motif or minimally a Ser/Thr-Pro motif. However, such sequences are relatively common within proteins, and other determinants of substrate specificity undoubtedly exist.
The MAPKs are final components of three-member MAPK cascades (Fig. 2 ). MAPKs are activated by MAPK kinases (MAPKKs, or MKKs) which catalyse the ordered dual phosphorylation of a Tyr and a Thr residue lying within a Thr-Xaa-Tyr motif of the MAPKs. The identity of the variable (Xaa) amino acid helps define MAPK subfamily membership (Table 3) . Activation of MAPKKs involves their phosphorylation on Ser/Thr residues by MAP-KK kinases (MAPKKKs). The nature of these cascades allows considerable potential for signal integration and amplification. The possibility for cross-talk between the pathways also exists because of apparently overlapping substrate specificities of some of the components of the cascades and of the upstream signalling molecules. However, studies on cross-talk have utilized largely in vitro methods or overexpression of proteins in transfected cell lines, and the physiological relevance of these findings remains to be established.
MAPK substrates
A variety of MAPK substrates have been identified, but here we focus on those that are most likely to be involved in hypertrophy, namely transcription factors and other protein kinases. There is considerable confusion in this area because most of the substrates can be phosphorylated by most MAPKs under in vitro conditions. The substrates which are phosphorylated preferentially by specific MAPKs in the . This may be particularly important in the regulation of c-jun transcription (one early response to hypertrophic stimulation or cell stress, reviewed in [1, 140] ) because the expression of c-jun is at least partly regulated through two cyclic AMP response element-like sequences (jun1 and jun2) in the c-jun promoter region [141] . Indeed, phosphorylation of both c-Jun and ATF2 in response to hypertrophic agonists or cellular stresses has been demonstrated in ventricular myocytes [142, 143] . p38-MAPK may also phosphorylate and activate MEF2 C [144] , a third transcription factor that may regulate expression of c-jun and other genes. Expression of c-fos mRNA is another early hallmark of the hypertrophic response. An important regulatory site in the c-fos gene is the serum response element (SRE; reviewed in [145, 146] ). All three MAPK subfamilies participate in the regulation of c-fos expression through the SRE (reviewed in [147] ). The ERKs [148] [149] [150] [151] [152] , the SAPKs/JNKs [151] [152] [153] [154] [155] and p38-MAPKs [149, 151, 152, 155] cooperate to phosphorylate and activate the ternary complex factors Elk1 and SAP1a, which act at the SRE in conjunction with another protein, the serum response factor (reviewed in [145, 146] ) to upregulate c-fos expression. Heterodimers of the c-Fos and c-Jun proteins bind to activator protein (AP1) regulatory sites present in the promoter regions of many genes, with phosphorylation of the cJun trans-activation domain increasing the trans-activating activity of the AP1 complex (reviewed in [156] ). Upregulation of the expression of both c-Fos and c-Jun may thus occur as a consequence of activation of MAPKs and presumably contributes to increased expression of a variety of other genes through binding to AP1 sites.
The MAPKs phosphorylate and activate a number of other protein kinases. One such kinase, MAPK-activated protein kinase-1/90 kDa ribosomal S6 kinase (MAP-KAPK1/p90 RSK ) is activated through the ERK cascade (see [157] for recent details) and is activated by hypertrophic agonists in myocytes [158] . Although originally thought to be involved in the regulation of translation, MAPKAPK1/p90 RSK , may instead be involved in the regulation of transcription, possibly through phosphorylation of serum response factor [159] and/or the transcriptional co-activator CBP [160] . p38-MAPKs phosphorylate and activate the MAPKAPK2 [161] and MAPKAPK3 [162] protein kinases, which in turn phosphorylate the small heat shock protein (Hsp) 25/27 [162, 163] . Phosphorylation of Hsp25/27 may increase its cytoprotective ability [164, 165] and may be important in cell survival (see below).
The ERK cascade
Regulation of the ERK cascade in the heart
The ERK cascade is the best characterized of the MAPK pathways (reviewed in [131, 134] the Raf family (c-Raf, A-Raf and B-Raf), the MAPKKs are MEK1 and MEK2 (MKK1 and MKK2), and the MAPKs are ERK1 (p44-MAPK) and ERK2 (p42-MAPK). An inhibitor of the ERK cascade (PD98059) is commercially available. The principal effect of PD98059 is to inhibit activation of MEK1 (in particular) and MEK2 by Raf [166, 167] and thus inhibit activation of ERKs by agonists. This compound is useful in implicating the participation of the ERK cascade in biological processes. The kinases at all three levels of the ERK cascade (Raf, MEK and ERK) are strongly activated by G q /G 11 protein coupled receptor agonists and PMA in the heart [124, [168] [169] [170] and by peptide growth factors [124, 171] . c-raf and A-raf transcripts, and c-Raf and A-Raf proteins are both present in rodent heart, as shown by northern or western blotting [170, 172] . The situation with respect to B-Raf is unclear. Whereas some investigators have failed to detect B-raf transcripts [172] or B-Raf protein [170] , it is now recognized that the B-raf gene gives rise to at least ten alternatively spliced transcripts and a number of the encoded proteins appear to be expressed at low levels (relative to nervous tissue) in murine heart [173] .
In ventricular myocytes, c-Raf and A-Raf activities are strongly stimulated by PMA and ET-1, with PE inducing a moderate activation [170] . The stimulation by PMA or ET-1 is detectable within 1 min and is maximal within approximately 3-5 min. Activation by ET-1 is transient and declines to near basal levels within approximately 30 min, whereas PMA stimulation is more sustained. Using chronic exposure of myocytes to PMA to down-regulate cPKCs/nPKCs, the activation of A-Raf by ET-1 can be clearly shown to be cPKC/nPKC dependent [170] . However, prolonged treatment with PMA increases basal c-Raf activity, complicating interpretation of data on cPKC/nPKC dependence [170] . Other pathways must also participate in the activation of A-Raf and c-Raf by ET-1 because PTX inhibits their activation by ET-1 [170] .
The mechanisms involved in the activation of Raf by PKC (reviewed in [94]) have not been definitively elucidated in any cell type. Evidence that PKC (cPKCα) directly phosphorylates and activates c-Raf has been presented [174] , but this has yet to be unambiguously confirmed. Activation of Raf by peptide growth factors acting through RPTKs has been extensively studied and involves interaction of a number of proteins (RPTKs, adapter proteins, guanine nucleotide exchange factors) which ultimately stimulates exchange of GDP for GTP on the small membrane-bound GTP-binding protein Ras (reviewed in [175] ). This pathway operates in G q /G 11 protein coupled receptor signalling in ventricular myocytes [176] where GPCR agonists increase Ras.GTP loading ( [176, 177] and A. Chiloeches and P.H. Sugden, unpublished observations). Very recently, clear evidence has been presented that PKC acts to increase Ras.GTP loading in noncardiomyocytes and that activation of ERKs by PKC is Ras dependent, although the mechanism is still unclear [178] . Similar results have also been obtained in ventricular myocytes (H.F. Paterson and P.H. Sugden, unpublished observations). Both c-Raf and A-Raf bind Ras.GTP (but not Ras.GDP), and this interaction translocates Raf from the soluble to the membrane fraction of the cell (reviewed in [179] ; see Fig. 1 ). Here tyrosine-phosphorylation of cRaf and A-Raf catalysed by Src family non-receptor protein tyrosine kinases may lead to their full activation [180, 181] . c-Raf is also phosphorylated on Ser/Thr residues [182] , but the function of these phosphorylations is unclear. Indeed, ANG II activates Src family kinases in myocytes, but the point of action of the Src kinases may be upstream of Ras [176] . At least one study in nonmyocytes has indicated that Ras.GTP and Src act independently rather than co-operatively to activate Raf [183] . The mode of activation of Raf is still controversial, and other studies have implicated different pathways in GPCRlinked activation of the ERK cascade (reviewed in [94] ).
The MEKs and ERKs are also strongly activated by PMA and ET-1 in ventricular myocytes and, consistent with the degree of Raf activation, α 1 -adrenergic agonists are less effective than PMA or ET-1 [124, 168, 184] . Activation of ERKs by ET-1 and α 1 -adrenergic agonists is transient (maximal at 5 min), whereas activation by PMA is more sustained. This activation is dependent on cPKCs/nPKCs [124], with PTX having little effect [103, 185] . Why the ET-1 induced activation of Raf [170] , but not the activation of ERKs [185] , is PTX sensitive is not understood, but it may be related to the innate amplification properties of the cascade. Although ANG II has been shown to activate components of the ERK cascade and upstream signalling molecules [158, 176, 186] , in our hands it is a relatively weak activator of ERKs in comparison to ET-1 and PMA [185] . Experiments with fluoroaluminate directly implicate G protein α subunits in the activation of ERKs in ventricular myocytes. Fluoroaluminate interacts with α subunits to form α.GDP.AlF 4 -species. These act as stable α.GTP analogues and in the case of α q .GDP.AlF 4 -activate PtdIns (4,5)P 2 hydrolysis. In myocytes, fluoroaluminate activates both PtdIns (4,5)P 2 hydrolysis and ERKs [185] . ET-1, PE and ANG II activate the ERKs in hearts in vivo and inhibition of G q /G 11 GPCR signalling blocks this activation [106] , indicating its importance in this situation.
Involvement of the ERK cascade in cardiac hypertrophy
In 1993 we proposed that the ERK cascade is involved in the hypertrophic response [168] . The initial evidence was that hypertrophic agonists (PMA, ET-1, norepinephrine) stimulate ERKs [124, 168] . Subsequent studies in our own and other laboratories have provided considerable support for this hypothesis. Thus, we found that transfection of ventricular myocytes with expression plasmids for mutated, constitutively activated MEK stimulates a hypertrophic pattern of gene expression [187] . Others, however, have found that transfection of constitutively activated MEK inhibits the stimulation of ANF expression by PE [188] , but this might be explained by a dominant-negative effect of the MEK mutant, which has a relatively low specific activity compared with the phosphorylated wild-type enzyme. Constitutively activated (oncogenic) Raf or constitutively activated Src also induces a hypertrophic pattern of gene expression and an increase in cell profile [189, 190] . Furthermore, depletion of ERK1 and ERK2 from myocytes by appropriate antisense oligodeoxynucleotides attenuates the stimulation of the hypertrophic pattern of gene expression by PE [191] .
Phospho-MAPK phosphatases (MKPs) dephosphorylate and thus inactivate MAPKs. MKP1 is absent from cells under basal conditions, but its expression is induced by activation of ERKs [192] . Transfection of MKPs thus maintains MAPKs in their unphosphorylated (inactive) forms. The hypertrophic pattern of gene expression induced by PE is inhibited by transfection of MKP1 [193] or the closely related CL100 phosphatase [188] . These results were interpreted as indicating participation of ERKs. However, although MKP1 was initially thought to be selective for ERKs, it was subsequently shown to dephosphorylate many phospho-MAPKs in vitro [194, 195] . The results should perhaps be more broadly interpreted as indicating involvement of MAPKs, rather than a specific MAPK subfamily.
The major problem with the transfection experiments involving constitutively activated components of the ERK cascade is that although they induce the transcriptional changes, no component clearly promotes the myofibrillogenesis that is so typical of the hypertrophic response [187] [188] [189] [190] 196] . However, PD98059 (which confusingly has been reported to potentiate ANF expression in some circumstance [197, 198] ) inhibits the myofibrillar organization induced by ET-1 or PE over 24 h (A. Clerk, A. Michael, PH. Sugden, submitted), suggesting that ERKs are important in this response. A further problem is that bradykinin (which stimulates the ERK cascade to a degree comparable to ET-1) is not strongly hypertrophic [123] , and indeed may be "anti-hypertrophic" [199] . Similar results have been obtained with carbachol or ATP [197] . These data indicate that whilst ERKs may be involved in the morphological changes, additional pathways are necessary. Confusingly (and in contrast to the results of the transfection experiments with constitutively activated Raf or MEK), neither PD98059 nor dominant-negative ERK constructs prevent the stimulation of ANF gene expression by PE [197] .
A recent view is that activation of the ERK cascade in the ventricular myocyte is not so much hypertrophic as anti-apoptotic [200] . In ventricular myocytes, CT-1 activates ERKs and confers a degree of cytoprotection. Inhibition of the ERK cascade by PD98059 or inhibitory constructs of MEK1 blocks the anti-apoptotic action, but not the hypertrophic action, of CT-1 [200] . These investigators attribute the hypertrophy induced by CT-1 to stimulation of the cytokine-regulated Janus kinases (JAK)/signal transducers and activators of transcription (STAT) pathway (see below). In support of this hypothesis, although PD98059 has no effect on the increase in cell profile induced by ET-1 or PE over 24 h (A. Clerk, A. Michael, PH. Sugden, submitted), after 48 h myocytes cultured in either agonist in the presence of PD98059 appear small, with poorly defined myofibrils ( [201] and A. Clerk, A. Michael, PH. Sugden, submitted). Our overall conclusion from these data is that the ERK cascade participates in hypertrophy, but that other pathways are also involved.
The "stress-regulated" MAPK cascades (SAPKs/JNKs and p38-MAPKs)
General aspects
The general function and nature of the "stress-regulated" MAPK cascades (SAPKs/JNKs and p38-MAPKs) have been recently reviewed [132, 133, 135, 202] , and reviews dealing more specifically with the cardiovascular system are also available [202, 203] . The SAPKs/JNKs are encoded by three genes, each of which produces multiple products by alternative splicing [204] . All isoforms typically migrate on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with apparent molecular masses of about 54 or 46 kDa. Likewise, a number of p38-MAPKs have been identified. There are two alternatively spliced variants of p38-MAPK (α) [161, 205] , and two of p38-MAPKβ [206, 207] , along with the p38-MAPKγ [208, 209] and the p38-MAPKδ isoforms [210] [211] [212] . Selective inhibitors of p38-MAPK (α) and p38-MAPKβ are available (SB203580, SB202190 [205, 207, 210, 213] ) and have been used to implicate p38-MAPK (α) and p38-MAPKβ in biological processes. As in all experiments involving the use of inhibitors, care needs to be taken with interpretation of data obtained because SB203580 inhibits some isoforms of SAPKs/JNKs [155, 214] .
In contrast to the ERK cascade, the upstream activators of the SAPKs/JNKs and p38-MAPKs are not well-defined (reviewed in [132, 135, 215, 216] ) and little work has been carried out in heart. In non-myocardial cells, MKK4 (also known as SEK1 or JNKK) and the recently identified MKK7 [217] appear to activate the SAPKs/JNKs selectively, whereas MKK3 and MKK6 are more selective for the p38-MAPKs. However, there may be cross-talk between the cascades (e.g. MKK4 may also phosphorylate the p38-MAPKs). The MAPKKKs for either cascade have not been fully characterized, but the MEKK group of MAPKKKs may be involved. A variety of proteins have been implicated upstream of the MAPKKKs. These include other protein kinases (e.g. PAKs, GCKs, MLKs; reviewed in [216, 218] ). Some of these upstream kinases may themselves be activated by small G proteins such as Rac and Cdc42 (reviewed in [215, 218] ). Ras also activates SAPKs/JNKs, and this may be mediated through activation of Rac/Cdc42 or MEKK (reviewed in [215] ). To our knowledge, the only one of these protein kinases placed above the MAPK level that has been shown to be activated in ventricular myocytes is αPAK (p21-activated kinase), which is activated by hyperosmotic stress and hypoxia but not by GPCR agonists or cytokines [219, 220] .
It is not clear whether activation of the "stress-regulated" MAPKs is beneficial or detrimental to the cell. Whilst promotion of gene transcription would intuitively be con-sidered to be anabolic, activation of "stress-regulated" MAPKs and increased c-jun expression may be involved in apoptosis [221] [222] [223] [224] [225] . Just as the duration of ERK activation may determine the balance between differentiation and proliferation in PC12 cells (reviewed in [226] ), the duration of SAPK/JNK activation may determine the balance between apoptosis and proliferation in T lymphocytes [227] . The duration of activation could similarly determine the balance between apoptosis and hypertrophy in myocytes. Equally, phosphorylation and activation of Hsp25/27 by p38-MAPKs should be cytoprotective rather than cytotoxic, and there is evidence that this is the case in endothelial cells [165] . As discussed in the next section, considerations of this nature are particularly relevant to the heart.
The SAPK/JNK and p38-MAPK cascades in the heart and their contribution to cardiac hypertrophy
The "stress-regulated" MAPKs are activated in perfused adult rat heart by ischaemia and/or reperfusion [228] [229] [230] . p38-MAPK and its substrate, MAPKAPK2 are activated by ischaemia alone, and this activation is maintained or increased during the reperfusion phase. SAPKs/JNKs are activated only during the reperfusion phase following ischaemia. Reactive oxygen species may contribute to this activation [231] , and these species also stimulate the "stress-regulated" MAPKs in ventricular myocytes [232, 233] . The differential activation of p38-MAPK and SAPKs/JNKs by ischaemia contrasts with most situations in other cells where the two MAPK pathways are activated concomitantly. In myocytes SAPKs/JNKs are strongly activated (approximately ten-fold) by cellular stresses such as hyperosmotic shock or the protein synthesis inhibitor, anisomycin [234] . Whether "stress-regulated" MAPKs are involved in cell death or are cardioprotective is not clear.
Surprisingly, SAPKs/JNKs [177, 234, 235] and p38-MAPKs ( [235, 236] and A. Clerk, A. Michael, PH. Sugden, submitted) are also activated in myocytes and perfused hearts by G q /G 11 GPCR agonists such as ET-1 or PE, although the activation is somewhat less than that by cellular stresses ( [234, 235] and A. Clerk, A. Michael, PH. Sugden, submitted). Other interventions that are potentially hypertrophic (stretch [237] , ANG II [238] , electrical pacing [31]) also activate the SAPKs/JNKs. These findings raise the possibility that SAPKs/JNKs and p38-MAPKs could be involved in the hypertrophic response. Indeed, activation of the SAPK/JNK cascade by MEKK1, MKK4 or MKK7 [177, 228, 239, 240] or transfection of constitutively activated (oncogenic) or wild-type c-jun [31, 241, 242] increases ANF expression (but paradoxically MEKK inhibits PE-induced myofibrillogenesis [239] ). There are two problems with the hypothesis that SAPKs/JNKs mediate the hypertrophic response. First, the powerfully hypertrophic agonist PMA does not activate the SAPKs/JNKs detectably [234] ,, but it is possible that its very strong sustained activation of the ERKs [124] could override the necessity for additional pathways. Secondly, the transfection experiments with MEKK and MKK4 are not unequivocal because of possible "crosstalk" between MAPK pathways [239, 243] . However, dominant-negative SAPK/JNK or c-Jun constructs inhibit MEKK-or PE-induced ANF expression [239] , specifically implicating that the SAPK/JNK cascade in this response.
Very recent reports have suggested that the p38-MAPK pathway may also contribute to the hypertrophic response [136, 201, 236, 244] , and additionally attenuate [244] or [in the case of p38-MAPK (α)] stimulate [136] apoptosis. Our recent data (A. Clerk, A. Michael, P.H. Sugden, submitted) indicate that SB203580 has no effect on the morphological changes induced by ET-1 or PE at up to 24 h, but at 48 h (in agreement with other studies [201, 236] ) myocytes treated with SB203580 appear small with poorly defined myofibrillar structure. These data suggest that p38-MAPK (α) and/or p38-MAPKβ is not involved in the development of a hypertrophic morphology, but is necessary over the longer time period, possibly reflecting a role in cell survival. In overall conclusion, we have arrived at a confused stage where all three well characterized MAPKs (ERKs, SAPKs/JNKs and p38-MAPKs) have been implicated in the hypertrophic response, and may in addition be either anti-apoptotic or pro-apoptotic!
The small GTP binding proteins and hypertrophy
The small GTP binding proteins (of which there are several subfamilies) play many important roles in cellular regulation. The Ras family (reviewed in [175, 215, 245] ) is implicated in the direct activation of the ERK cascade (see above) and the phosphatidylinositol 3-OH kinase (PI3 K) pathway (see below). They may also activate the "stressregulated" MAPKs indirectly through Rac/Cdc42. The Rho family (RhoA, Rac and Cdc42) are involved in the regulation of cell morphology and cytoskeletal organization (reviewed in [246] [247] [248] ) and, in the case of Rac and Cdc42, in the activation of "stress-regulated" MAPKs (reviewed in [215] ).
Microinjection of constitutively activated (oncogenic) V12Ras protein or adenoviral-mediated transfer of V12Ras into myocytes induces a full hypertrophic response (modulation of gene transcription, and increases in cell profile and myofibrillar assembly), and dominant-negative Ras attenuates PE-stimulated ANF expression [249] [250] [251] . However, results with transfection of expression plasmids encoding V12Ras are not as definitive with little evidence of myofibrillar assembly [190, 252] . The stimulation of ANF expression by V12Ras may be dependent on the level of cfos expression [242] . Furthermore, Ras may act as a pleiotropic rather than a specific stimulator of gene expression in myocytes [253] . In vivo, cardiospecific expression of V12Ras in transgenic mice causes development of cardiac hypertrophy [254] , providing further evidence for the involvement of Ras in this response.
In addition to activating the ERK cascade, Ras may also activate Rho family proteins (reviewed in [215] ). There is now a considerable body of literature to indicate the involvement of Rho in hypertrophy [239, 251, 255, 256] . Experimental approaches have used RhoA inhibitors (the C. botulinum C3 exonuclease inhibitor of RhoA, transfection of inhibitory constructs of RhoA) to implicate it in the responses of myocytes to agonist stimulation, and transfection of a variety of constitutively activated or inhibitory constructs of RhoA, Ras, MEKK, and α q . The overall conclusion is that Ras and RhoA induce a hypertrophic response by separate, complementary, synergistic pathways, such as the ERK and SAPK/JNK cascades [198, 239, 255] . Furthermore, a number of Rho-dependent protein kinases have been identified recently (reviewed in [248] ), and inhibitory constructs of one such kinase prevents some aspects of hypertrophy induced by RhoA or PE [251] . The involvement of RhoA and RhoA-dependent kinases in hypertrophy awaits further clarification. Studies on the roles of Rac and Cdc42 in hypertrophy are relatively limited. Zechner et al. [236] have shown induction of hypertrophic marker genes by constitutively activated Rac, and from the patterns of activation of the three MAPK subfamilies, this could be mediated by the SAPKs/JNKs. More studies are needed here.
The JAK/STAT pathway
The JAKs were first identified as protein tyrosine kinases associated with cytokine receptors (reviewed in [257] ). In outline, binding of ligands to these receptors leads to receptor oligomerization and tyrosine-phosphorylation of the receptor-JAK complex. These phosphorylations recruit transcription factors of the STAT family to the complex where they become tyrosine-phosphorylated. Several isoforms of the JAKs (JAK1, JAK2, JAK3, Tyk2) and the STATs (STATs 1-6) have so far been identified, and selective association of specific JAK and STAT isoforms with different cytokine receptors subtypes has been demonstrated. In addition to activation through cytokine receptors, STATs may also be activated by some peptide growth factors through their RPTKs. The phosphorylated STATs dimerize and migrate into the nucleus to activate gene transcription through the sis-inducible element and the interferon-γ activation site/interferon-α stimulated response element. Alternatively, STATs may interact with other transcription factors to transactivate gene expression in a co-operative manner.
Relatively little is known about regulation of the JAK/STAT pathway in the ventricular myocyte (reviewed in [55]). As mentioned above, the cytokine homolog CT-1 may promote ventricular myocyte hypertrophy through activation of the JAK/STAT pathway [200] , although the evidence is preliminary and essentially correlative. However, leukaemia inhibitory factor (a protein related to CT-1 which also couples to gp130/IL-6 receptor) has recently be shown to stimulate the JAK/STAT pathway in ventricular myocytes [258] . The JAK/STAT pathway is also activated by ANG II in ventricular myocytes [258] [259] [260] and other cell types [261] [262] [263] , leading to increased binding of STATs to sis-inducible elements in the promoter regions of genes [258] [259] [260] . A recent report has implicated the JAK/STAT pathway in ANG II dependent pressure-overload hypertrophy in vivo [264] , but whether the JAK/STAT pathway plays any role in myocyte hypertrophy requires further investigation.
Pathways involving Ca 2+ and other ions?
Although it is controversial in some cases (see, e.g. [265] [270] . Any influence of Ca 2+ on reversible protein phosphorylation and the hypertrophic response may be exerted not so much via protein phosphorylation as through protein dephosphorylation. Thus transgenic mice that overexpress the sarcoplasmic reticulum Ca 2+ binding protein calsequestrin develop a hypertrophy of unknown aetiology [271] . A putative mechanism by which Ca 2+ regulates hypertrophy involves the Ca 2+ /calmodulin-dependent protein phosphatase, calcineurin [272] . The activation of calcineurin may promote dephosphorylation of the cytoplasmic transcription factor, NF-AT3, allowing it to migrate into the nucleus and interact with the GATA4 transcription factor (reviewed in [273] ) to upregulate expression of genes such as brain natriuretic peptide. Transgenic mice expressing constitutively activated calcineurin or NF-AT3 develop hypertrophy [272] . Furthermore, hypertrophy in cultured myocytes induced by PE or ANG II is diminished by the immunosuppressant drugs, cyclosporin A and FK506, which interact with their cognate binding proteins (cyclophilin and FKBP12, respectively) to inhibit calcineurin. The results with FK506 are not easily reconciled with those of Boluyt et al. [274] , who showed that FK506 reversed the inhibition of PE-induced hypertrophy by a third immunosuppressant, rapamycin [an inhibitor of p70 S6K activation (see below)]. However, the demonstration of a potential involvement of calcineurin may open up a new approach to the biological understanding and treatment of cardiac hypertrophy, as it emphasizes the importance of protein dephosphorylation.
Because both interact with common carboxyl groups on Ca 2+ -binding proteins, Ca 2+ i and intracellular pH (pH i ) are interdependent with increased pH i raising Ca 2+ i . Agonists such as ET-1, α 1 -adrenergic agents, and ANG II have been reported to increase pH i probably through activation of the Na + /H + exchanger (reviewed in [275, 276] ). There are indications that pH i is important in hypertrophy since increased pH i stimulates the expression of hypertrophic marker genes [277] . Although work in non-myocardial cells places MAPKs upstream of the Na + /H + exchanger, this may not be the case in myocytes. Thus inhibition of Na + /H + exchange blocks stretch-induced activation of MAPKs [278] , and hence could potentially block development of the hypertrophic phenotype.
Translational control in hypertrophy
Cardiac protein mass is increased in hypertrophy, and this is brought about in part by an increase in the rate of protein synthesis. It is a general finding that hypertrophic agonists acutely stimulate the rate of protein synthesis in the heart (reviewed in [33] ), a fact that is all too frequently ignored. The overall rate of protein synthesis is determined by both its efficiency (the rate at which the nascent peptide chains are synthesized per ribosome) and its capacity (the relative abundance of ribosomes) (reviewed in [33] ). Efficiency is regulated principally at the level of initiation, i.e. formation of the 80 S ribosome/mRNA/methionyl-tRNA initiation complex (reviewed in [279] ). The molecular mechanisms regulating translational initiation have not been studied in the heart but could involve PI3K-dependent pathways (see below). Equally, with respect to the previous section on ion handling, it should be borne in mind that increased pH i is a potent stimulator of protein synthesis in the heart [280] , and this may be involved the positive effects of hypertrophic agonists on this process [281] .
In the longer term, ribosome abundance is modulated and is clearly increased in hypertrophy (reviewed in [34] ). Ribosomes are complexes of ribosomal proteins and ribosomal RNA (rRNA). rRNA is synthesized as a 45-S precursor from rDNA in the nucleolus by DNA-dependent RNA polymerase 1 and is later processed into 28 S, 18 S and 5.8 S rRNAs. The regulation of rRNA transcription has been studied extensively in the heart where it is controlled by the transcription factor upstream binding factor (UBF) 1 (reviewed in [34] ). PMA [282] , ET-1 [282] , adrenergic agonists [283] and contraction [284] increase the rate of rDNA transcription, and this has been shown in some cases to be correlated with the serine-phosphorylation of UBF [282] . ET-1-induced phosphorylation of UBF is inhibited by the PKC-selective inhibitor Ro 318220 [282] . The protein kinases responsible for UBF phosphorylation have not been identified, but the data are consistent with the involvement of the PKC/ERK pathway.
The phosphatidylinositol 3-OH kinase pathway and the control of translation The PI3 K pathway ( Fig. 3 ; reviewed in [285] [286] [287] ) is an area that is of immense interest at the moment because it may represent the dominant pathway through which insulin and IGF1 exert their biological effects. Insulin, IGF1 and other growth factors stimulate tyrosine-autophosphorylation of their RPTKs. The insulin and IGF-1 RPTKs also tyrosine-phosphorylate the insulin receptor substrates 1 and 2 (reviewed in [288] ). An 85-kDa regulatory subunit of PI3 K binds to specific phosphotyrosine residues in the RPTKs (or insulin receptor substrates). This interaction activates an associated 110-kDa PI3 K catalytic subunit which catalyses the phosphorylation of membrane PtdIns (4,5)P 2 to PtdIns (3,4,5)P 3 . The involvement of PI3 K in biological processes can be implicated by the use of the PI3 K inhibitors, wortmannin and LY294002 (reviewed in [285] ). There may be other mechanisms of activation of PI3 K. Thus Ras may bind to and activate the catalytic subunit of PI3 K directly, and GPCRs may activate certain isoforms of PI3 K (reviewed in [287] ).
The PtdIns (3,4,5)P 3 formed from phosphorylation of PtdIns (4,5)P 2 remains in the membrane, where it may fulfil at least two signalling roles (reviewed in [286] ). First, it activates the recently identified PtdIns (3,4,5)P 3 -dependent protein kinases (PDK) 1 and 2 ( [289] and reviewed in [290] ). Secondly, it may bind another protein kinase, B (PKB/Akt), and place it in the vicinity of PDK which phosphorylates and activates it. Activation of PKB/Akt leads to the phosphorylation and modulation of the activities of a number of proteins, including (phosphorylatable heat-and acid-stable protein I regulated by insulin (PHAS-I) and p70 S6K . Both of these proteins are intimately con- Fig. 3 The PI3 K pathway. Binding of peptide growth factors to RPTKs causes autophosphorylation of tyrosyl-residues in their intracellular domains. The regulatory (85-kDa) subunit of PI3 K binds to specific phosphotyrosyl-residues, and this activates the 110-kDa catalytic subunit (which may also interact with activated, membranebound Ras.GTP). PI3 K phosphorylates (phosphorylation events are denoted by ~P) PtdIns (4,5)P 2 to PtdIns (3,4,5)P 3 . This may translocate PKB/Akt to the membrane where it is phosphorylated and activated by PDK1/2. Activation of PKB/Akt leads to phosphorylation of p70 S6K and PHAS-I, and thus to activation of protein synthesis translation, in a pathway involving mTOR. The number of stages and the means by which the signal is transmitted from PKB/Akt to p70 S6K and PHAS-I are not clear (dashed lines) cerned with the regulation of protein synthesis. Phosphorylation of both PHAS-I and p70 S6K is probably mediated by another protein kinase, mammalian target of rapamycin (mTOR; also known as FRAP, RAFT1, RAPT1 and SEP), which may be activated downstream from PI3 K and PKB/Akt (reviewed in [291] ). The involvement of mTOR in biological responses is implicated by sensitivity to the immunosuppressant, rapamycin (reviewed in [292] ). Rapamycin interacts with a 12-kDa protein (FKBP-12) to form a complex which inhibits mTOR. A related immunosuppressant, FK506, also binds FKBP-12, but this complex does not inhibit mTOR and thus FK506 antagonizes the inhibitory effects of rapamycin on mTOR. p70 S6K is probably the principle kinase involved in the phosphorylation of the small ribosomal subunit protein S6 (reviewed in [293] ). Phosphorylation of S6 promotes the selective translation of mRNA species containing polypyrimidine tracts in their 5' untranslated regions. The role of p70 S6K in modulating the overall rate of protein synthesis is therefore likely to be limited and confined to this restricted group of mRNAs, which includes messages for ribosomal proteins and translation elongation factors. Its role is thus more likely to be facilitative, being concerned with the upregulation of the translational machinery in order to allow increased protein synthesis.
A second mechanism of regulation of translation is through PHAS-I (in the rat) and its human homologs (eIF4E-BP1 and 2; reviewed in [294] ). In its dephosphorylated state PHAS-I associates with the eukaryotic initiation factor (eIF) 4 E and prevents binding of eIF4 E to the 7-methyl-GTP cap lying at the 5' ends of many mRNA species. Binding of eIF4 E to the 7-methyl-GTP cap is necessary for the formation of the translational initiation complex. This step (reviewed in [279] ) is rate limiting for translation in eukaryotic cells. Phosphorylation of PHAS-I dissociates the eIF4 E/PHAS-I complex, allowing the initiation complex to form. Phosphorylation of PHAS-I was initially thought to be mediated by the ERK pathway, but recent evidence has implicated mTOR (reviewed in [294] ). Although initiation of translation is the rate-limiting step for translation under many conditions, additional points of regulation may exist (e.g. phosphorylation of eIF4 E and eukaryotic elongation factor 2 [279, 295, 296] ). Indeed, phosphorylation of eIF4 E is induced by cardiac load and may contribute to the increase in protein synthesis during hypertrophy [297] .
The PI3 K pathway in the heart Few studies have been performed in the heart, but in view of the fact that insulin and IGF1 powerfully stimulate cardiac protein synthesis [298] [299] [300] , involvement of the PI3 K pathway might be anticipated. IGF1, which additionally induces the transcriptional changes seen in hypertrophy [62] , stimulates phosphorylation of PtdIns (4,5)P 2 to PtdIns (3,4,5)P 3 in myocytes [171] . Furthermore, the hypertrophic agonists PMA, α 1 -adrenergic agents and ET-1 stimulate cardiac protein synthesis [301] [302] [303] and the PI3 K pathway may provide a mechanism for achieving this. Although PI3 K is stimulated by α 1 -adrenergic agonists in vascular smooth muscle cells [304] , it is not known whether it is stimulated by hypertrophic GPCR agonists in myocytes. However, inhibitors of the PI3 K/mTOR pathway (wortmannin, LY294002 and rapamycin) block the stimulation of p70 S6K activity and protein synthesis by PE [274] . The increase in cell profile induced by PE is also prevented by rapamycin, the effects of which are antagonized by FK506. Importantly, rapamycin does not inhibit the stimulation of expression of ANF or SkM-α-actin mRNA induced by PE, suggesting that transcription of hypertrophic genes and protein synthesis are regulated by distinct pathways. The stimulatory effects of ANG II on myocyte protein synthesis (but not on c-fos expression [305] ) are also mediated by a rapamycin-sensitive pathway and may involve p70 S6K [305, 306] . Although PHAS-I is Fig. 4 A scheme for the development of the hypertrophic phenotype in heart. GPCR agonists such as ET-1 or PE stimulate transcription by activating one or more MAPK cascades, thus causing the phosphorylation of transcription factors (see Fig. 2 ). At the same time, they increase protein synthesis translation possibly through the PI3 K pathway (see Fig. 3 ). This allows the heart to increase its total protein mass and to initiate a hypertrophic pattern of gene expression. Agonists such as insulin stimulate only the PI3 K pathway and therefore promote protein synthesis but do not stimulate the hypertrophic pattern of gene expression present in the heart [307] 
An overall scheme for signalling in ventricular myocyte hypertrophy
Any scheme that sets out to define the signalling pathways involved in myocyte hypertrophy must explain the ability of hypertrophic agonists to stimulate a hypertrophic programme of gene expression, to increase overall rates of protein synthesis, and to promote myofibrillar assembly. Equally, any scheme needs to account for the ability of anabolic hormones such as insulin to stimulate protein synthesis in the absence of the changes in gene expression that typify hypertrophy. We propose (Fig. 4) that G q /G 11 GPCR agonists simulate membrane phospholipid hydrolysis and cPKCs/nPKCs. This leads to activation of Ras and subsequently one or more MAPK cascades. Ultimately this induces the transcriptional changes in myocyte hypertrophy. Some RTPK agonists may also activate Ras in myocytes to cause similar changes. Other pathways (e.g. the JAK/STAT pathway) may contribute to transcriptional modulation. We suggest that hypertrophic G q /G 11 protein coupled receptor and RPTK agonists additionally stimulate the PI3 K pathway to increase translation, thus having a permissive effect on hypertrophy. We further propose that insulin acts through the PI3 K pathway to stimulate protein synthesis, but since it does not stimulate ERKs in the heart [169] , it does not induce a full hypertrophic response. This would allow cardiac protein mass to be coupled to the nutritional state of the animal (reviewed in [33] ) without the exhibiting the transcriptional changes associated with hypertrophy. The mechanisms that regulate myofibrillar assembly remain poorly understood, and their investigation is warranted. 
